Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes -: implications for cost-effectiveness analyses

被引:75
|
作者
van Valkengoed, IGM
Morré, SA
van den Brule, AJC
Meijer, CJLM
Bouter, LM
Boeke, AJP
机构
[1] Vrije Univ Amsterdam Med Ctr, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Sect Mol Pathol, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam Med Ctr, Immunogenet Lab, Amsterdam, Netherlands
[4] PAMM Inst, Lab Pathol & Med Microbiol, Eindhoven, Netherlands
关键词
mass screening; Chlamydia trachomatis; salpingitis; pelvic inflammatory disease; infertility; costs and cost analysis; ectopic pregnancy;
D O I
10.1093/ije/dyh029
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Cost-effectiveness analyses of screening programmes for asymptomatic Chlamydia trachomatis infection suggest that screening at low prevalences in the population is cost-effective. However, the decision models in these studies are based on assumptions about the risk of complications, which are derived from the literature. Incorrect assumptions may lead to under- or overestimation of the effectiveness of screening. The first objective of this paper is to evaluate the assumptions about the probability of complications after an asymptomatic C. trachomatis infection. The second objective is to calculate alternative rates by using available data on the incidence of complications. Methods We identified cost-effectiveness studies via Medline, and evaluated these for the evidence for the quoted probabilities. In addition, the probability of complications was calculated for Amsterdam from available registration data. Results In the three studies that were identified, the assumptions for the rates of pelvic inflammatory disease (PID) (clinical and subclinical) after C. trachomatis infection varied from 15% to 80%, and for ectopic pregnancy, tubal factor infertility, and chronic pelvic pain after PID from 5-25%, 10-20%, and 18-30%, respectively. The assumptions were based on data from high-risk populations, case-control data, and data not accounting for misdiagnoses. Using data obtained from local registrations, we estimated the probability of a clinical PID (0.43%), ectopic pregnancy (0.07%), and tubal factor infertility (0.02%) for women with a current infection. These estimates were consistently lower than the estimates based on the literature. Conclusions We argue that an overestimation of the current complication rates is likely. The effect of overestimation is potentially the greatest in populations with a low prevalence, since the currently assumed cost savings associated with screening may disappear when using more realistic estimates for complications.
引用
收藏
页码:416 / 425
页数:10
相关论文
共 50 条
  • [1] The cost and cost-effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland
    Gillespie, Paddy
    O'Neill, Ciaran
    Adams, Elisabeth
    Turner, Katherine
    O'Donovan, Diarmuid
    Brugha, Ruairi
    Vaughan, Deirdre
    O'Connell, Emer
    Cormican, Martin
    Balfe, Myles
    Coleman, Claire
    Fitzgerald, Margaret
    Fleming, Catherine
    SEXUALLY TRANSMITTED INFECTIONS, 2012, 88 (03) : 222 - 228
  • [2] Cost-effectiveness of a pharmacy-based screening for Chlamydia trachomatis
    van Bergen, JE
    Postma, MJ
    Peerbooms, PG
    Spangenberg, AC
    Tjen-A-Tak, J
    Bindels, PJ
    VALUE IN HEALTH, 2003, 6 (06) : 754 - 755
  • [3] Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening
    Land, J. A.
    Van Bergen, J. E. A. M.
    Morre, S. A.
    Postma, M. J.
    HUMAN REPRODUCTION UPDATE, 2010, 16 (02) : 189 - 204
  • [4] The Cost-Effectiveness of Screening Men for Chlamydia trachomatis: A Review of the Literature
    Gift, Thomas L.
    Blake, Diane R.
    Gaydos, Charlotte A.
    Marrazzo, Jeanne M.
    SEXUALLY TRANSMITTED DISEASES, 2008, 35 (11) : S51 - S60
  • [5] COST-EFFECTIVENESS OF SCREENING FOR CHLAMYDIA TRACHOMATIS IN DUTCH PREGNANT WOMEN
    Rours, G. I. J. G.
    Verkooijen, R. P.
    Verbrugh, H. A.
    Postma, M. J.
    SEXUALLY TRANSMITTED INFECTIONS, 2011, 87 : A61 - A61
  • [6] COST-EFFECTIVENESS OF PRE-NATAL SCREENING FOR CHLAMYDIA TRACHOMATIS
    NETTLEMAN, MD
    CLINICAL RESEARCH, 1988, 36 (06): : A874 - A874
  • [7] Dynamic modelling for estimating the cost-effectiveness of a Chlamydia trachomatis screening program
    de Vries, R.
    van Bergen, J. E. A. M.
    de Jong-van den Berg, L. T. W.
    Postma, M. J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 736 - 736
  • [8] Dynamic modelling for estimating the cost-effectiveness of a Chlamydia trachomatis screening program
    De Vries, R
    Postma, MJ
    De Jong-van den Berg, LT
    Van Bergn, J
    VALUE IN HEALTH, 2005, 8 (06) : A57 - A57
  • [9] Cost-effectiveness of two screening strategies for Chlamydia Trachomatis infections in France
    Préaubert, N
    Delaveyne, R
    VALUE IN HEALTH, 2003, 6 (06) : 758 - 758
  • [10] Cost-effectiveness analysis of Chlamydia trachomatis screening in Dutch pregnant women
    Rours, G. I. J. G.
    Smith-Norowitz, Tamar Anne
    Ditkowsky, Jared
    Hammerschlag, Margaret R.
    Verkooyen, R. P.
    de Groot, R.
    Verbrugh, H. A.
    Postma, M. J.
    PATHOGENS AND GLOBAL HEALTH, 2016, 110 (7-8) : 292 - 302